Még nem toboroz
Low-Dose Radiotherapy for Painful Knee Osteoarthritis
NCT07886697· Universidad Rey Juan Carlos· Forrás
Contact: Dolores López, MD
Toboroz
A Study to Evaluate the Safety and Efficacy of Two Dose Levels of ONO-4578 With Opdivo®, in Combination With mFOLFOX6 and Bevacizumab Versus Standard of Care in Participants With Non-MSI-H/dMMR, PD-L1 Positive Advanced Colorectal Cancer
NCT06948448· 2. fázis· Ono Pharmaceutical Co., Ltd.· Forrás
Contact: North America Clinical Trial Support Desk
Toboroz
A study to evaluate acalabrutinib, in combination with the R-CHOP standard of care, for previously untreated mantle cell lymphoma in Spain.
2025-521152-34-00· 2. fázis· Astrazeneca Farmaceutica Spain S.A.· Forrás
Toboroz
Sotorasib combined with first-line chemotherapy for advanced pancreatic adenocarcinoma
2024-516233-12-00· 1. fázis· Asociacion Grupo Tratamiento De Tumores Digestivos· Forrás
Toboroz
CRF2 Agonist for the Treatment of Worsening Heart Failure
NCT06815471· 2. fázis· Corteria Pharmaceuticals· Forrás
Toboroz
PALACE: Cemiplimab Trial According to ctDNA Levels
NCT06917573· 2. fázis· Fundación GECP· Forrás
Toboroz
Neoadjuvant Tebentafusp in Patients With Metastatic Uveal Melanoma
NCT07057596· 2. fázis· Grupo Español Multidisciplinar de Melanoma· Forrás
Toboroz
Neoadjuvant Treatment With Atezolizumab and Atezolizumab as Maintenance for the Treatment of Stage III Non Small-Cell Lung Cancer (NSCLC)
NCT07153445· 2. fázis· Fundación GECP· Forrás
Fut, nem toboroz
A Study to Assess the Change in Disease Activity in Adult Participants With Moderate to Severe Ulcerative Colitis Treated With Risankizumab Compared to Vedolizumab
NCT06880744· 3. fázis· AbbVie· Forrás
Toboroz
Encorafenib and biNimetinib Followed by CEmiplimab and FiAnLimab in Patients With BRAF Mutant melanOma and Symptomatic Brain Metastases
NCT06887088· 2. fázis· Grupo Español Multidisciplinar de Melanoma· Forrás
Toboroz
A Study of Zolbetuximab Together With Pembrolizumab and Chemotherapy in Adults With Gastric Cancer
NCT06901531· 3. fázis· Astellas Pharma Global Development, Inc.· Forrás
Toboroz
Is CT 01 safe to use alone or combined with Everolimus for inoperable advanced liver cancer?
2024-511435-10-00· 1. fázis· Captor Therapeutics S.A.· Forrás
Fut, nem toboroz
A study to investigate the efficacy and safety of subcutaneous sonelokimab versus placebo in participants aged 18 years and over with active psoriatic arthritis who are naive to biologic DMARDs
2024-516213-20-00· 3. fázis· MoonLake Immunotherapeutics AG· Forrás
Toboroz
A Study to Compare the Efficacy and Safety of BMS-986489 (Atigotatug+ Nivolumab Fixed Dose Combination) in Combination With Carboplatin Plus Etoposide to That of Atezolizumab With Carboplatin Plus Etoposide as First-Line Therapy in Participants With Extensive-Stage Small Cell Lung Cancer (TIGOS).
NCT06646276· 3. fázis· Bristol-Myers Squibb· Forrás
Toboroz
Phase II study of Roginolisib in UM patients
2024-514333-37-00· 2. fázis· iOnctura SA· Forrás
Toboroz
Sotorasib, Panitumumab and FOLFIRI Versus FOLFIRI With or Without Bevacizumab-awwb in Treatment-naïve Subjects With Metastatic Colorectal Cancer With KRAS p.G12C Mutation (CodeBreaK 301)
2022-502352-31-00· 3. fázis· Amgen Inc.· Forrás
Fut, nem toboroz
A Phase 3 Study to Assess Efficacy Safety and Tolerability of Remibrutinib in Adult and Adolescent Patients With Moderate to Severe Hidradenitis Suppurativa (RECHARGE 1)
NCT06799000· 3. fázis· Novartis Pharmaceuticals· Forrás
Toboroz
Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer (ROSETTA Lung-02)
NCT06712316· 2/3. fázis· BioNTech SE· Forrás
Toboroz
DEBSCAN-IVL. Drug Eluting Balloon or Drug Eluting Stent to Treat CAlcified Nodules After IntraVascular Lithotripsy.
NCT06657833· Fundación EPIC· Forrás
Contact: FUNDACION EPIC
Toboroz
Elacestrant + Everolimus in Patients ER+/HER2-, ESR1mut, Advanced Breast Cancer Progressing to ET and CDK4/6i.
NCT06382948· 3. fázis· MedSIR· Forrás
Toboroz
Randomised, double-blind, multicentre, phase III clinical trial to evaluate the efficacy and safety of dexamethasone compared to placebo in patients with severe influenza (FLUDEX)
2024-513209-30-00· 3. fázis· Fundacion De La Comunitat Valenciana Para La Gestion Del Instituto De Investigacion Sanitaria Y Biomedica De Alicante· Forrás
Fut, nem toboroz
A Study of Cemiplimab Plus Chemotherapy Versus Cemiplimab Plus Chemotherapy Plus Other Cancer Treatments for Adult Patients With Operable Non-Small Cell Lung Cancer (NSCLC)
NCT06465329· 2. fázis· Regeneron Pharmaceuticals· Forrás
Toboroz
The Sagittarius Trial
NCT06490536· 3. fázis· IFOM ETS - The AIRC Institute of Molecular Oncology· Forrás
Toboroz
A Phase II Randomized, Open Label Non-inferiority Study of NiraParib Maintenance After 3 vs. 6 Cycles of Platinum-based Chemotherapy in completeLy debUlked Advanced HRDpositive High-grade Ovarian Cancer patientS in First Line Therapy
NCT05460000· 2. fázis· North Eastern German Society of Gynaecological Oncology· Forrás
Toboroz
Study to Compare Bictegravir/Lenacapavir Versus Current Therapy in People With HIV-1 Who Are Successfully Treated With Biktarvy
NCT06333808· 3. fázis· Gilead Sciences Inc.· Forrás
Fut, nem toboroz
A Follow-up Study to Test Long-term Treatment With Nerandomilast in People With Pulmonary Fibrosis Who Took Part in a Previous Study With Nerandomilast
NCT06238622· 3. fázis· Boehringer Ingelheim· Forrás
Toboroz
CRS Questionnaire Validation Project
NCT06970977· The European Forum for Research and Education in Allergy and Airway Diseases· Forrás
Contact: Ainhoa García Lliberós de Miguel
Fut, nem toboroz
A Study to Assess Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Children From 2 to Less Than 12 Years of Age With Moderate to Severe Atopic Dermatitis
NCT06461897· 3. fázis· AbbVie· Forrás
Fut, nem toboroz
PHESGO Maintenance After T-DXd Short Induction for HER2+ Unresectable Locally Recurrent or Metastatic Breast Cancer
NCT06172127· 2. fázis· MedSIR· Forrás
Toboroz
Study of Sotorasib, Panitumumab and FOLFIRI Versus FOLFIRI With or Without Bevacizumab-awwb in Treatment-naïve Participants With Metastatic Colorectal Cancer With KRAS p.G12C Mutation
NCT06252649· 3. fázis· Amgen· Forrás
Fut, nem toboroz
A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa
NCT06468228· 3. fázis· AbbVie· Forrás
Fut, nem toboroz
Effectiveness and Safety of Lebrikizumab Treatment in Adults and Adolescents with Moderate-to-Severe Atopic Dermatitis
2023-508235-31-00· 3. fázis· Almirall S.A.· Forrás
Toboroz
A Study to Test Whether Vicadrostat in Combination With Empagliflozin Helps People With Heart Failure
NCT06424288· 3. fázis· Boehringer Ingelheim· Forrás
Toboroz
A Trial to Evaluate the Efficacy and Safety of Tralokinumab in Combination With Topical Corticosteroids in Children and Infants With Moderate-to-severe Atopic Dermatitis
NCT06311682· 3. fázis· LEO Pharma· Forrás
Toboroz
Phase 3 Extension Study to Evaluate Long-term Safety of Ianalumab in Participants With Systemic Lupus Erythematosus (SIRIUS-SLE Extension).
NCT06133972· 3. fázis· Novartis Pharmaceuticals· Forrás
Toboroz
Bevacizumab plus encorafenib-cetuximab in BRAF-V600E mutated metastatic colorectal cancer, a phase II study with a safety lead-in cohort, the BRAVE trial
2023-509204-15-00· 2. fázis· Vall D Hebron Institute Of Oncology· Forrás
Toboroz
A Study to Test Whether BI 764524 Helps People With an Eye Condition Called Diabetic Retinopathy
NCT06321302· 2. fázis· Boehringer Ingelheim· Forrás
Fut, nem toboroz
A Study to Evaluate the Efficacy, Safety, and Tolerability of Using an Oral Once-daily 2 Drug Regimen Compared to an Oral Once-daily 3 Drug Regimen for the Treatment of Human Immunodeficiency Virus (HIV)-1 in Adults Who Have Not Previously Taken Antiretroviral Therapy
NCT05979311· 3. fázis· ViiV Healthcare· Forrás
Fut, nem toboroz
A Study to Evaluate ABP 206 Compared with OPDIVO® (Nivolumab) in Subjects with Unresectable or Metastatic Melanoma
2023-503288-40-00· 3. fázis· Amgen Inc.· Forrás
Fut, nem toboroz
A Study To Assess Adverse Events and Effectiveness of Upadacitinib Oral Tablets in Adult and Adolescent Participants With Vitiligo
NCT06118411· 3. fázis· AbbVie· Forrás
Fut, nem toboroz
Saruparib (AZD5305) vs Placebo in Men With Metastatic Castration-Sensitive Prostate Cancer Receiving Physician's Choice New Hormonal Agents
NCT06120491· 3. fázis· AstraZeneca· Forrás
Fut, nem toboroz
IDE196 (Darovasertib) in Combination With Crizotinib as First-line Therapy in Metastatic Uveal Melanoma
NCT05987332· 2/3. fázis· IDEAYA Biosciences· Forrás
Fut, nem toboroz
Disitamab Vedotin With Pembrolizumab vs Chemotherapy in Previously Untreated Urothelial Cancer Expressing HER2
NCT05911295· 3. fázis· Seagen, a wholly owned subsidiary of Pfizer· Forrás
Toboroz
Study of Personalized Allocation of Defibrillators in Non-ischemic Heart Failure (SPANISH-1)
NCT06055504· Consorcio Centro de Investigación Biomédica en Red (CIBER)· Forrás
Contact: Aurelio Quesada Dorador (principal investigator)
Toboroz
Study of Perioperative Dostarlimab in Participants With Untreated T4N0 or Stage III dMMR/MSI-H Resectable Colon Cancer
NCT05855200· 3. fázis· GlaxoSmithKline· Forrás
Fut, nem toboroz
ONC-392 Versus Docetaxel in Metastatic NSCLC That Progressed on PD-1/PD-L1 Inhibitors
NCT05671510· 3. fázis· OncoC4, Inc.· Forrás
Fut, nem toboroz
Adagrasib in Patients With KRASG12C-mutant NSCLC Who Are Elderly or Have Poor Performance Status
NCT05673187· 2. fázis· ETOP IBCSG Partners Foundation· Forrás
Fut, nem toboroz
A Study of Orforglipron (LY3502970) in Adult Participants With Obesity or Overweight With Weight-Related Comorbidities
NCT05869903· 3. fázis· Eli Lilly and Company· Forrás
Fut, nem toboroz
DUMAS: Neo-Adjuvant Immunotherapy for Pancoast Tumors
NCT05684276· 2. fázis· Fundación GECP· Forrás
Fut, nem toboroz
HERMES – A research study to look at how ziltivekimab works compared to placebo in people with heart failure and inflammation.
NCT05636176· 3. fázis· Novo Nordisk A/S· Forrás
Showing 50 of 88.